IPOs and Secondaries
IPOs and Secondaries Articles
Ra Pharmaceuticals expects to price its almost 6 million shares in the range of $12 to $14 per share for an initial public offering valued up to more than $93 million.
Published:
Last Updated:
All four of last week’s initial public offering (IPO) candidates succeeded in reaching the public markets. The results were definitely a mixed bag although the first IPO of an oil & gas...
Published:
Last Updated:
Ocean Power Technologies shares fell sharply on Friday after the company announced the pricing of its secondary offering.
Published:
ZTO Express intends to price around 72 million shares in a range of $16.50 to $18.50 for an initial public offering valued up to more than $1 billion.
Published:
Last Updated:
Oilfield services firm Extraction Energy Services priced more than 7 million shares at $15 (the low end of its expected range) for its Friday initial public offering, but the stock opened nearly 9%...
Published:
Last Updated:
Ra Pharmaceuticals filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No pricing details were given in the filing, but in the previous...
Published:
Last Updated:
Myovant Sciences has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Accelerated Pharma intends to price less than 2 million shares in the range of $8 to $10 for an initial public offering valued up to more than $21 million.
Published:
Last Updated:
Azure Power Global expects to price more than 3 million shares in the range of $21 to $23 per share for an initial public offering valued up to more than $90 million.
Published:
Last Updated:
iRhthym Technologies intends to list more than 5 million shares in the price range of $13 to $15 for an initial offering valued up to more than $92 million.
Published:
Last Updated:
Twilio and fellow unicorn Acacia Communications are having secondary offerings to cash in on their massive runs over the summer.
Published:
Last Updated:
All six of last week’s initial public offering (IPO) candidates succeeded in reaching the public markets. And while none had quite the introduction that welcomed Nutanix the week before, another...
Published:
Last Updated:
The late-summer doldrums are over and the markets are on the move again as we are now in the fourth quarter. But a few companies held the market back from pushing even higher.
Published:
Last Updated:
CRISPR Therapeutics expects to price more than 4 million shares in the range of $15 to $17 apiece for an initial public offering valued up to nearly $92 million.
Published:
Forterra expects to price more than 18 million shares in the range of $19 to $21 apiece for an initial public offering valued up to more than $444 million.
Published:
Last Updated: